Can trastuzumab be included in medical insurance in 2024?

In the medical field of breast cancer treatment, Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is like a shining star, showing impressive therapeutic effects with its innovative antibody conjugation technology. Although this original drug has been launched in the domestic market, it has not yet successfully entered the ranks of medical insurance. So, in the future in 2024, will trastuzumab have a chance to enter the arms of medical insurance? The answer to this question is not easy to achieve overnight. It involves multiple factors such as the therapeutic effect of the drug, cost considerations, market demand, and the formulation of medical insurance policies.

As a high-profile innovative drug, trastuzumab has a unique therapeutic mechanism. It targets HER2-positive breast cancer cells and successfully blocks the growth signal of cancer cells by attaching to the HER2 protein through its unique fam-trastuzumab moiety. At the same time, its topoisomerase I inhibitor chemotherapy part further improves the therapeutic effect by interfering with the replication ability of cells. This unique dual mechanism of action makes trastuzumab show significant advantages in the treatment of HER2-positive or low-expression breast cancer, not only significantly prolonging the patient's survival, but also reducing the risk of disease progression.

In addition, with the increasing number of breast cancer patients and the continuous expansion of trastuzumab in gastric cancer, non-small cell lung cancer and other fields, its market demand is also continuing to rise. This trend undoubtedly lays a solid foundation for Trastuzumab's future medical insurance path. If the production cost of trastuzumab can be gradually reduced in the future, and its efficacy and safety continue to be verified, then the possibility of it entering the medical insurance catalog will be greatly increased.